Patents by Inventor Gayathri Swaminath
Gayathri Swaminath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240327461Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.Type: ApplicationFiled: June 11, 2024Publication date: October 3, 2024Applicant: AMGEN INC.Inventors: Jerry Ryan HOLDER, Gayathri SWAMINATH, Michael J. FROHN, Brian Alan LANMAN, Anthony B. REED, Leslie P. MIRANDA, John Gordon ALLEN, Alexander J. PICKRELL, Aaron C. SIEGMUND, Lewis D. PENNINGTON, Bryant YANG
-
Patent number: 11807693Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.Type: GrantFiled: January 28, 2021Date of Patent: November 7, 2023Assignee: AMGEN INC.Inventors: Jerry Ryan Holder, Gayathri Swaminath, Michael J. Frohn, Brian Alan Lanman, Anthony B. Reed, Leslie P. Miranda, John Gordon Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
-
Patent number: 11191762Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.Type: GrantFiled: November 3, 2017Date of Patent: December 7, 2021Assignee: AMGEN INC.Inventors: Yinhong Chen, Mikkel V. Debenedetto, Paul John Dransfield, James S. Harvey, Jonathan Houze, Aarif Yusuf Khakoo, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Vatee Pattaropong, Gayathri Swaminath, Wen-Chen Yeh, Philip Dean Ramsden, Ankit Sharma
-
Publication number: 20210261619Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.Type: ApplicationFiled: January 28, 2021Publication date: August 26, 2021Inventors: Jerry Ryan HOLDER, Gayathri SWAMINATH, Michael J. FROHN, Brian Alan LANMAN, Anthony B. REED, Leslie P. MIRANDA, John Gordon ALLEN, Alexander J. PICKRELL, Aaron C. SIEGMUND, Lewis D. PENNINGTON, Bryant YANG
-
Patent number: 11046680Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.Type: GrantFiled: November 3, 2017Date of Patent: June 29, 2021Assignee: AMGEN INC.Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, James S. Harvey, Julie Anne Heath, Lars V. Heumann, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Frank Kayser, Aarif Yusuf Khakoo, David J. Kopecky, Su-Jen Lai, Zhihua Ma, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Malgorzata Wanska, Kevin Yang, Wen-Chen Yeh
-
Patent number: 11020395Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein.Type: GrantFiled: November 3, 2017Date of Patent: June 1, 2021Assignee: AMGEN INC.Inventors: Yinhong Chen, Paul John Dransfield, James S. Harvey, Julie Anne Heath, Jonathan Houze, Aarif Yusuf Khakoo, David J. Kopecky, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Vatee Pattaropong, Gayathri Swaminath, Wen-Chen Yeh, Philip Dean Ramsden
-
Patent number: 10941182Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.Type: GrantFiled: June 10, 2015Date of Patent: March 9, 2021Assignee: Amgen Inc.Inventors: Jerry Ryan Holder, Gayathri Swaminath, Michael J. Frohn, Brian Alan Lanman, Anthony B. Reed, Leslie P. Miranda, John G. Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
-
Patent number: 10906890Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.Type: GrantFiled: November 3, 2017Date of Patent: February 2, 2021Assignee: AMGEN INC.Inventors: Ning Chen, Yinhong Chen, Mikkel V. Debenedetto, Paul John Dransfield, James S. Harvey, Julie Anne Heath, Jonathan Houze, Aarif Yusuf Khakoo, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Vatee Pattaropong, Gayathri Swaminath, Wen-Chen Yeh, Charles Kreiman
-
Patent number: 10736883Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.Type: GrantFiled: November 3, 2017Date of Patent: August 11, 2020Assignee: AMGEN INC.Inventors: Matthew Brown, Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, James S. Harvey, Julie Anne Heath, Lars V. Heumann, Jonathan Houze, Frank Kayser, Aarif Yusuf Khakoo, David j. Kopecky, Su-Jen Lai, Zhihua Ma, Julio C. Medina, Jeffrey T. Mihalic, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Malgorzata Wanska, Wen-Chen Yeh
-
Patent number: 10689367Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein.Type: GrantFiled: November 3, 2017Date of Patent: June 23, 2020Assignee: AMGEN INC.Inventors: Yinhong Chen, Alan C. Cheng, Mikkel V. Debenedetto, Paul John Dransfield, James S. Harvey, Jonathan Houze, Aarif Yusuf Khakoo, Su-Jen Lai, Zhihua Ma, Vatee Pattaropong, Gayathri Swaminath, Charles Kreiman, David C. Moebius, Ankit Sharma
-
Publication number: 20190300507Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, I or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein.Type: ApplicationFiled: November 3, 2017Publication date: October 3, 2019Applicant: AMGEN INC.Inventors: Yinhong CHEN, Alan C. CHENG, Mikkel V. DEBENEDETTO, Paul John DRANSFIELD, James S. HARVEY, Jonathan HOUZE, Aarif Yusuf KHAKOO, Su-Jen LAI, Zhihua MA, Vatee PATTAROPONG, Gayathri SWAMINATH, Charles KREIMAN, David C. MOEBIUS, Ankit SHARMA
-
Publication number: 20190290647Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.Type: ApplicationFiled: November 3, 2017Publication date: September 26, 2019Applicant: AMGEN INC.Inventors: Yinhong CHEN, Mikkel V. DEBENEDETTO, Paul John DRANSFIELD, James S. HARVEY, Jonathan HOUZE, Aarif Yusuf KHAKOO, Su-Jen LAI, Zhihua MA, Nobuko NISHIMURA, Vatee PATTAROPONG, Gayathri SWAMINATH, Wen-Chen YEH, Philip Dean RAMSDEN, Ankit SHARMA
-
Publication number: 20190290648Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein.Type: ApplicationFiled: November 3, 2017Publication date: September 26, 2019Applicant: AMGEN INC.Inventors: Yinhong CHEN, Paul John DRANSFIELD, James S. HARVEY, Julie Anne HEATH, Jonathan HOUZE, Aarif Yusuf KHAKOO, David J. KOPECKY, Su-Jen LAI, Zhihua MA, Nobuko NISHIMURA, Vatee PATTAROPONG, Gayathri SWAMINATH, Wen-Chen YEH, Philip Dean RAMSDEN
-
Publication number: 20190284173Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.Type: ApplicationFiled: November 3, 2017Publication date: September 19, 2019Applicant: AMGEN INC.Inventors: Ning CHEN, Yinhong CHEN, Mikkel V. DEBENEDETTO, Paul John DRANSFIELD, James S. HARVEY, Julie Anne HEATH, Jonathan HOUZE, Aarif Yusuf KHAKOO, Su-Jen LAI, Zhihua MA, Nobuko NISHIMURA, Vatee PATTAROPONG, Gayathri SWAMINATH, Wen-Chen YEH, Charles KREIMAN
-
Publication number: 20190275008Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.Type: ApplicationFiled: November 3, 2017Publication date: September 12, 2019Applicant: AMGEN INC.Inventors: Matthew BROWN, Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, James S. HARVEY, Julie Anne HEATH, Lars V. HEUMANN, Jonathan HOUZE, Frank KAYSER, Aarif Yusuf KHAKOO, David j. KOPECKY, Su-Jen LAI, Zhihua MA, Julio C. MEDINA, Jeffrey T. MIHALIC, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Malgorzata WANSKA, Wen-Chen YEH
-
Patent number: 10221162Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.Type: GrantFiled: July 12, 2018Date of Patent: March 5, 2019Assignee: AMGEN INC.Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
-
Publication number: 20180319773Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.Type: ApplicationFiled: July 12, 2018Publication date: November 8, 2018Applicant: AMGEN INC.Inventors: Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, Julie Anne HEATH, Daniel B. HORNE, Jonathan HOUZE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Su-Jen LAI, Zhihua MA, Lawrence R. MCGEE, Julio C. MEDINA, Jeffrey T. MIHALIC, Nobuko NISHIMURA, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Kevin YANG, Wen-Chen YEH, Mikkel V. DEBENEDETTO, Robert P. FARRELL, Simon J. HEDLEY, Ted C. JUDD, Frank KAYSER
-
Patent number: 10058550Abstract: Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.Type: GrantFiled: June 21, 2017Date of Patent: August 28, 2018Assignee: AMGEN INC.Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Zice Fu, Julie Anne Heath, Daniel B. Horne, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Zhihua Ma, Jeffrey T. Mihalic, Gayathri Swaminath, Xiaodong Wang, Wen-Chen Yeh
-
Patent number: 9988369Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.Type: GrantFiled: May 2, 2017Date of Patent: June 5, 2018Assignee: AMGEN INC.Inventors: Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Mikkel V. Debenedetto, Paul John Dransfield, Zice Fu, James S. Harvey, Julie Anne Heath, Simon J. Hedley, Jonathan Houze, Ted C. Judd, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Wen-Chen Yeh
-
Patent number: 9868721Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.Type: GrantFiled: October 19, 2016Date of Patent: January 16, 2018Assignee: AMGEN INC.Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser